August 31, 2020

Mylan and Biocon Biologics have launched Semglee™ (insulin glargine injection) in vial and pre-filled pen dosage forms. The product is FDA-approved to help control blood sugar in adult and pediatric patients who have type 1 diabetes and adults diagnosed with type 2 diabetes.

Semglee has the same amino acid sequence as its reference product, Lantus® (insulin glargine injection – Sanofi), and is approved for the same indications. However, it is not automatically interchangeable. Mylan and Biocon are currently seeking to have Semglee designated as a Lantus biosimilar by the FDA.

Mylan and Biocon have priced Semglee at a 65% discount to Lantus, with a wholesale acquisition cost (WAC) of $147.98 per package of five 3mL pens and $98.65 per 10mL vial. This is the lowest WAC for any long-acting insulin glargine currently on the U.S. market.

September 23, 2020

Updated Black Box Warning for Benzodiazepines

Read More
September 23, 2020

Sun Pharmaceuticals Voluntarily Recalls One Lot of Riomet ER

Read More
September 22, 2020

Perrigo Voluntarily Recalls Albuterol Inhalers

Read More
September 17, 2020

FDA Withdraws Approval for Belviq and Belviq XR

Read More